HUP0003160A2 - CD40:CD154-Kötődést akadályozó ágens alkalmazása hasnyálmirigyszigetek transzplantációját követően a szövetgrafttal szembeni tolerancia elősegítésére alkalmas gyógyszer előállítására - Google Patents

CD40:CD154-Kötődést akadályozó ágens alkalmazása hasnyálmirigyszigetek transzplantációját követően a szövetgrafttal szembeni tolerancia elősegítésére alkalmas gyógyszer előállítására

Info

Publication number
HUP0003160A2
HUP0003160A2 HU0003160A HUP0003160A HUP0003160A2 HU P0003160 A2 HUP0003160 A2 HU P0003160A2 HU 0003160 A HU0003160 A HU 0003160A HU P0003160 A HUP0003160 A HU P0003160A HU P0003160 A2 HUP0003160 A2 HU P0003160A2
Authority
HU
Hungary
Prior art keywords
pangreatic
enhancing
preparation
inhibiting agent
tolerance against
Prior art date
Application number
HU0003160A
Other languages
English (en)
Inventor
Linda Burkly
Norma S. Kenyon
Camillo Ricordi
David W. Thomas
Original Assignee
Biogen, Inc.
University Of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc., University Of Miami filed Critical Biogen, Inc.
Publication of HUP0003160A2 publication Critical patent/HUP0003160A2/hu
Publication of HUP0003160A3 publication Critical patent/HUP0003160A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • External Artificial Organs (AREA)
  • Steroid Compounds (AREA)

Abstract

Atalálmány tárgya CD40:CD154 kötődést akadályozó ágens alkalmazásafőemlősökben inzulintermelő szövetgraft kilökődésének gátlására vagyvisszafordítására, túlélésének meghosszabbítására, továbbáfunkciójának megőrzésére vagy helyreállítására szolgáló gyógyszerelőállítására, valamint glükózanyagcsere metabolikus szabályozásánakfőemlősben történő helyreállítására szolgáló gyógyszer előállítására.ACD40:CD154 kötődést akadályozó ágens előnyösen monoklonálisellenanyag, előnyösebben az 5c8 elnevezésű, ATCC HB10916nyilvántartási számú ellenanyag antigénspecifikus kötődésisajátságaival rendelkező monoklonális ellenanyag. Atalálmány tárgyatovábbá eljárás glükózanyagcsere metabolikus szabályozását érintőkárosodás kimutatására emlősben. Ó
HU0003160A 1997-06-20 1998-06-19 The use of cd40:cd154-binding inhibiting agent for the preparation of pharmaceuticals used for enhancing of tolerance against tissue graft after pangreatic islet tissue transplantation HUP0003160A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5026797P 1997-06-20 1997-06-20
US7726598P 1998-03-09 1998-03-09

Publications (2)

Publication Number Publication Date
HUP0003160A2 true HUP0003160A2 (hu) 2001-01-29
HUP0003160A3 HUP0003160A3 (en) 2002-09-30

Family

ID=26728084

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003160A HUP0003160A3 (en) 1997-06-20 1998-06-19 The use of cd40:cd154-binding inhibiting agent for the preparation of pharmaceuticals used for enhancing of tolerance against tissue graft after pangreatic islet tissue transplantation

Country Status (22)

Country Link
US (2) US20030072754A1 (hu)
EP (1) EP1051191B1 (hu)
JP (1) JP2002506446A (hu)
KR (1) KR100634847B1 (hu)
CN (2) CN1195546C (hu)
AT (1) ATE339966T1 (hu)
AU (1) AU730763B2 (hu)
BG (1) BG64976B1 (hu)
BR (1) BR9810620A (hu)
CA (1) CA2294154A1 (hu)
DE (1) DE69835965T2 (hu)
EA (1) EA002550B1 (hu)
EE (1) EE9900588A (hu)
HK (1) HK1033548A1 (hu)
HU (1) HUP0003160A3 (hu)
IL (1) IL133303A0 (hu)
IS (1) IS5273A (hu)
NO (1) NO996275L (hu)
NZ (1) NZ502052A (hu)
SK (1) SK180299A3 (hu)
TR (1) TR199903142T2 (hu)
WO (1) WO1998058669A2 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045958A1 (en) * 1998-03-09 1999-09-16 Biogen, Inc. Cd154 blockade therapy for modulation of immune responses to implanted devices
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2410786A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of Minnesota Immunotherapeutic method to prevent islet cell rejection
KR20030007899A (ko) * 2000-06-09 2003-01-23 브리스톨-마이어스스퀴브컴파니 림프구성 신호의 차단 및 ｌｆａ-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법
CA2528551A1 (en) * 2003-06-13 2005-01-13 Biogen Idec Ma Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
JP2008520235A (ja) * 2004-11-22 2008-06-19 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド インスリンを産生可能な拡大され、かつ再分化した成体島β細胞の集団およびその作製方法
WO2007047539A2 (en) * 2005-10-14 2007-04-26 Medtronic, Inc. Localized delivery to the lymphatic system
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
WO2010093467A1 (en) * 2009-02-10 2010-08-19 The Trustees Of Columbia University In The City Of New York Methods for inducing transplantation tolerance
WO2011146395A2 (en) 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10147463B2 (en) 2014-12-10 2018-12-04 Nxp Usa, Inc. Video processing unit and method of buffering a source video stream
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
KR101810778B1 (ko) * 2015-06-23 2017-12-20 서울대학교산학협력단 Cd154 결합 폴리펩타이드 및 그 용도
US10986309B2 (en) 2015-06-30 2021-04-20 Nxp Usa, Inc. Video buffering and frame rate doubling device and method
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227298A (en) * 1990-08-17 1993-07-13 The Trustees Of Columbia University In The City Of New York Method for microencapuslation of cells or tissue
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
BR9810620A (pt) 2000-10-03
HUP0003160A3 (en) 2002-09-30
US20030072754A1 (en) 2003-04-17
NZ502052A (en) 2001-01-26
CN1195546C (zh) 2005-04-06
HK1033548A1 (en) 2001-09-07
KR20010013965A (ko) 2001-02-26
IS5273A (is) 1999-11-26
CN1651919A (zh) 2005-08-10
NO996275L (no) 2000-02-21
EA200000058A1 (ru) 2000-08-28
EP1051191A2 (en) 2000-11-15
KR100634847B1 (ko) 2006-10-17
CA2294154A1 (en) 1998-12-30
AU730763B2 (en) 2001-03-15
EE9900588A (et) 2000-08-15
BG104091A (en) 2000-10-31
CN1261286A (zh) 2000-07-26
EP1051191B1 (en) 2006-09-20
DE69835965T2 (de) 2007-06-14
JP2002506446A (ja) 2002-02-26
EA002550B1 (ru) 2002-06-27
IL133303A0 (en) 2001-04-30
WO1998058669A2 (en) 1998-12-30
BG64976B1 (bg) 2006-11-30
AU7983098A (en) 1999-01-04
NO996275D0 (no) 1999-12-17
WO1998058669A3 (en) 1999-04-29
ATE339966T1 (de) 2006-10-15
TR199903142T2 (xx) 2000-09-21
DE69835965D1 (de) 2006-11-02
US20070292440A1 (en) 2007-12-20
SK180299A3 (en) 2000-06-12

Similar Documents

Publication Publication Date Title
HUP0003160A2 (hu) CD40:CD154-Kötődést akadályozó ágens alkalmazása hasnyálmirigyszigetek transzplantációját követően a szövetgrafttal szembeni tolerancia elősegítésére alkalmas gyógyszer előállítására
ATE269054T1 (de) Konfekt zusammensetzungen
DK0841904T3 (da) Orale farmaceutiske præparater med forsinket frigivelse af reversible protonpumpeinhibitorer
NO993979L (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor
EP0919234A3 (en) Potentiation of pharmaceuticals by moxonidine
DK0721346T3 (da) Fremgangsmåde til induktion af antigenspecifik T-celletolerance
BR0311325A (pt) Métodos e composições para aliviar a dor
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
NO20054607L (no) Nitrogenholdig heterosyklisk derivat som har 2,6-disubstituert styryl
BR0309837A (pt) Forma de administração trans-epicutânea para tratamento da sìndrome das pernas inquietas
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
FR2682041B1 (fr) Vaccin contre les infections a neisseria meningitidis.
NO20055187L (no) Fremgangsmate for behandling og forebygging av lavere urinkanal symptomer
PT692028E (pt) Farmacos baseados em papilomavirus
EA200200207A1 (ru) Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы
Kneteman et al. THE METABOLIC IMPACT OF RAPAMYCIN (SIROLIMUS) IN CHRONIC CANINE ISLET GRAFT RECIPIENTS1
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
DK1154795T3 (da) Middel til behandling af diagnosticering af restless legs syndrom
DK1024822T3 (da) CD8 som inhibitor for det cellulære immunsystem
NO962655D0 (no) Deutrerte virkestoffer i transdermal applikasjon
GEP20063774B (en) Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders
BR0010179A (pt) Dispositivo de montagem apropriado para uso com uma armação para toalha de tecido de banheiro convencional
NO944214L (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
Ehrenpreis et al. Further studies on the analgesic activity of D-phenylalanine (DPA) in mice and humans
DK1058544T3 (da) Inhibition af TNF-aktivitet med præparater, der omfatter heparin og oplöselige TNF-receptorer